← The Wire·Breaking·Regulation·

Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say

Kimberly-Clark is preparing asset sales to secure EU approval for its proposed Kenvue deal, according to sources cited by Investing.com. The concessions could reduce regulatory friction but add execution risk and raise questions about the transaction’s eventual scope.

STOCK PHOTO · PIXABAY

The story

Kimberly-Clark is readying asset sales as it seeks approval from European Union regulators for its proposed acquisition of Kenvue, according to people familiar with the matter.

The move comes as Kimberly-Clark works to clear the deal with competition authorities rather than treating the transaction as a solely commercial combination. The EU may be considering whether asset sales would be sufficient to resolve its concerns.

For Kimberly-Clark, the mechanism is direct: divestitures could make the transaction more acceptable to regulators, but they could also remove brands, products or operations from the combined business and add separation costs. Kenvue is the consumer-health company involved in the deal; its reported FY2025 revenue was $15.1B, while Kimberly-Clark reported FY2025 revenue of $16.4B.

The next decisive markers are Kimberly-Clark's disclosure of any remedy package, a formal European Commission decision, and the companies' next results updates. Open questions remain about whether the sales would materially change the deal economics and whether regulators in other jurisdictions require additional concessions.

Our read · Mon, Sep 14

The reported asset sales keep the Kenvue transaction viable for KMB but shift the risk toward a smaller or less valuable deal.

Why. The setup is balanced: concessions could preserve Kimberly-Clark’s access to Kenvue, but undisclosed divestitures may dilute the strategic and financial benefits before approval is secured. The reported FY2025 revenue bases—$16.4B for KMB and $15.1B for KVUE—underline the scale of the combination, while the absence of remedy details prevents a stronger directional read.

Both cases

The case it holdsAsset sales could address the EU’s concerns and keep the proposed Kenvue combination on track.
The case it breaksThe reported need for divestitures signals that approval may require concessions that reduce the deal’s value; the assets and terms remain undisclosed.

What could change this view: The trade is invalidated by a formal EU remedy package that materially shrinks the transaction or by regulators rejecting the deal.

Kimberly Clark stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 1

Keep reading

More on KMB

Kimberly-Clark completes Kenvue deal, forming a global health platformKimberly-Clark seeks EU approval for $40 billion Kenvue deal

Latest on the Wire

Walmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackTrump Media buys back $100 million of notes ahead of Nov. 30 cash demandContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic Said to Guide IPO Pricing Above Market RangeNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Investing.com, . Who answers for this

The only report in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →